NCT06868576View on ClinicalTrials.gov

PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

February 28, 2025

Conditions
PPOSGnRH AntagonistAssisted Reproductive Techniques
Interventions
DRUG

Dydrogesterone Oral Tablet

Dydrogesterone 20mg tablets daily in PPOS protocol in ovarian stimulation starting from day 2 or 3 of the menstrual cycle until the triggering day

DRUG

Cetrorelix (Cetrotide)

This will be the conventional antagonist in ovarian stimulation given from day 6 of the menstrual cycle until the triggering day

Trial Locations (1)

11835

Ciro University Kasr Alainy OBGYN Hospital, Cairo

All Listed Sponsors
lead

Kasr El Aini Hospital

OTHER